LeonaBio, Inc. (LONA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LeonaBio, Inc. (LONA) has a cash flow conversion efficiency ratio of -0.698x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.40 Million) by net assets ($27.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LeonaBio, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how LeonaBio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does LeonaBio, Inc. carry for a breakdown of total debt and financial obligations.
LeonaBio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LeonaBio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daejoo Inc
KQ:003310
|
0.035x |
|
Orthex Oyj
HE:ORTHEX
|
0.158x |
|
Kapsch Traffic
VI:KTCG
|
0.636x |
|
U-Best Polymer Industry Co Ltd
TWO:4714
|
0.000x |
|
Investigator Resources Ltd
AU:IVR
|
-0.020x |
|
Artiva Biotherapeutics, Inc. Common Stock
NASDAQ:ARTV
|
-0.149x |
|
GreenTree Hospitality Group Ltd
NYSE:GHG
|
0.083x |
|
Curo Co Ltd
KO:015590
|
0.134x |
Annual Cash Flow Conversion Efficiency for LeonaBio, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of LeonaBio, Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see LeonaBio, Inc. (LONA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.79 Million | $-45.73 Million | -1.646x | +24.06% |
| 2024-12-31 | $44.84 Million | $-97.17 Million | -2.167x | -180.01% |
| 2023-12-31 | $130.19 Million | $-100.75 Million | -0.774x | -151.11% |
| 2022-12-31 | $235.14 Million | $-72.47 Million | -0.308x | -129.61% |
| 2021-12-31 | $321.08 Million | $-43.10 Million | -0.134x | -52.68% |
| 2020-12-31 | $274.28 Million | $-24.11 Million | -0.088x | -146.70% |
| 2019-12-31 | $-19.72 Million | $-3.71 Million | 0.188x | -37.48% |
| 2018-12-31 | $-14.89 Million | $-4.48 Million | 0.301x | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds whic… Read more